Search

Your search keyword '"Nwizu, Tobenna I."' showing total 5 results
Start Over Author "Nwizu, Tobenna I."
5 results on '"Nwizu, Tobenna I."'

4. Risk Factors Associated with Disease Recurrence in Patients with Stage III/IV Squamous Cell Carcinoma of the Oral Cavity Treated with Surgery and Postoperative Radiotherapy.

Author

Noble AR, Greskovich JF, Han J, Reddy CA, Nwizu TI, Khan MF, Scharpf J, Adelstein DJ, Burkey BB, and Koyfman SA

Subjects
Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Chemoradiotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Female, Head and Neck Neoplasms mortality, Head and Neck Neoplasms pathology, Humans, Kaplan-Meier Estimate, Lymph Node Excision, Lymphatic Metastasis, Male, Middle Aged, Mouth pathology, Mouth Neoplasms mortality, Mouth Neoplasms pathology, Neoplasm Staging, Neoplasm, Residual, Oral Surgical Procedures mortality, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Risk Assessment, Risk Factors, Squamous Cell Carcinoma of Head and Neck, Time Factors, Treatment Outcome, Young Adult, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy, Mouth radiation effects, Mouth surgery, Mouth Neoplasms therapy, Neoplasm Recurrence, Local, Oral Surgical Procedures adverse effects
Abstract

Aim: The purpose of the present study was to identify variables associated with high risk of failure in patients with locally advanced squamous cell carcinoma of the oral cavity (SCC-OC)., Patients and Methods: This retrospective study included 191 patients with stage III-IVb SCC-OC treated with post-operative radiotherapy (RT) or chemoradiotherapy (CRT) between 1995 and 2013. Disease-free (DFS) and overall survival (OS) were analyzed; variables associated with inferior DFS were identified., Results: Seventy-five patients (39%) recurred. DFS and five-year OS were 52% and 54%, respectively. Poorly differentiated tumors (p=0.03), recurrent tumors (p=0.02) and high nodal ratio (p=0.02) were associated with an increased risk of recurrence. CRT was associated with improved DFS in patients with positive margins and/or extracapsular extension (p=0.021)., Conclusion: Tumors that are recurrent, high grade, or have high nodal ratio are at risk of recurrence. Presence of these disease features should be taken into consideration for better risk stratification., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2016

5. Early and Severe Radiation Toxicity Associated with Concurrent Sirolimus in an Organ Transplant Recipient with Head and Neck Cutaneous Squamous Cell Carcinoma: A Case Report.

Author

Manyam BV, Nwizu TI, Rahe ML, Harr BA, and Koyfman SA

Subjects
Aged, Carcinoma, Squamous Cell etiology, Carcinoma, Squamous Cell pathology, Chemoradiotherapy adverse effects, Head and Neck Neoplasms etiology, Head and Neck Neoplasms pathology, Humans, Immunosuppressive Agents adverse effects, Male, Neoplasm Staging, Prognosis, Skin Neoplasms etiology, Skin Neoplasms pathology, Carcinoma, Squamous Cell therapy, Head and Neck Neoplasms therapy, Liver Transplantation adverse effects, Radiation Injuries etiology, Radiotherapy, Adjuvant adverse effects, Sirolimus adverse effects, Skin Neoplasms therapy
Abstract

We present a case of a 71-year-old man with a history of liver transplantation who was treated with adjuvant radiotherapy with concurrent cisplatin for recurrent cutaneous squamous cell carcinoma of the head and neck. The patient was transitioned from tacrolimus to sirolimus for immunosuppression immediately prior to the start of radiation therapy, with the goal of reducing the risk for further skin cancer recurrence. The patient developed severe normal tissue toxicity, disproportionate to the dose delivered. He was diagnosed with Grade 4 esophagitis and mucositis after just 2,400 cGy in 12 fractions (planned 6,400 cGy in 32 fractions), requiring cessation of therapy. Six months later, the patient was diagnosed with local recurrence and distant metastases in the lung, and unfortunately passed away one month later. Randomized data have demonstrated the anti-neoplastic benefit of sirolimus. Pre-clinical studies and animal models have suggested that sirolimus may be a radiation sensitizer; however, the literature is limited regarding the clinical translation of these biologic findings. The case we presented reflects that concurrent radiation therapy with sirolimus may enhance the cytotoxic effects of radiation therapy and contribute to dose-limiting toxicity. Certainly, further study is necessary to explore this observation., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results